The CASP9 Knockout CAL-27 Polyclonal Cells represent a loss-of-function model generated by CRISPR/Cas9-mediated disruption of the human CASP9 gene in the CAL-27 oral squamous cell carcinoma (OSCC) line. This product is supplied as a polyclonal knockout cell population, providing a heterogeneous pool of edited cells suitable for pooled functional studies and pathway analysis. The targeted disruption of CASP9 ablates expression of the initiator procaspase-9 protein, enabling researchers to dissect its role in intrinsic apoptosis without clonal isolation artifacts.
The host cell line, CAL-27, is an adherent epithelial line originally derived from a squamous cell carcinoma of the tongue in a 56-year-old male. Widely employed as a model for OSCC, it retains key features of epithelial tumor biology, including deregulated proliferation and apoptotic resistance, making it relevant for studying oral carcinogenesis and therapeutic responses.
Caspase-9 functions as the apical initiator caspase of the intrinsic apoptotic pathway. Upon cytochrome c release from mitochondria, it associates with Apaf-1 to assemble the apoptosome, where procaspase-9 undergoes proximity-induced activation. Active caspase-9 subsequently cleaves and activates effector caspases-3 and -7, which proteolyze key substrates including PARP, ICAD/DFF45, and lamin A/C to execute apoptosis. This signaling cascade is tightly regulated by upstream BCL-2 family members (BAX, BAD, BID) and p53, while the inhibitor XIAP directly binds and suppresses caspase-9, -3, and -7 activity, a process counteracted by the mitochondrial protein SMAC/DIABLO. Additionally, molecular chaperones Hsp70 and Hsp90 interact with procaspase-9 and Apaf-1, modulating apoptosome formation, while antiapoptotic proteins BCL-2 and BCL-XL preserve mitochondrial integrity to prevent cytochrome c release.
In the CAL-27 oral squamous cell carcinoma background, CASP9 knockout severely compromises the intrinsic apoptotic machinery, allowing dissection of resistance mechanisms that promote cell survival under genotoxic or therapeutic stress. This model is particularly valuable for investigating how loss of caspase-9-dependent signaling impacts response to chemotherapy, radiotherapy, or targeted agents that engage mitochondrial apoptosis, and for studying the interplay between survival pathways and the apoptosome in head and neck cancer.
The polyclonal knockout population supports diverse applications, including comparative apoptosis signaling studies, drug resistance profiling, and identification of alternative cell death pathways. Commonly used assays include Western blot analysis of caspase-9, caspase-3, and PARP cleavage; fluorometric caspase-9 activity measurements; cytochrome c release assays from mitochondrial fractions; flow cytometry with Annexin V/PI staining for apoptosis quantification; and cell viability assays. Immunofluorescence detection of activated caspase-9 and RT-qPCR for CASP9 transcript levels further validate the model. For additional product details or custom inquiries, please contact Ascent Research.
